See the full story in the original article.
Read the original on whnz.iheart.com ↗
Related news
- Medicare Open Enrollment Begins , 2027 Plan Changes Announced
Medicare open enrollment starts Thursday, October 15, and runs until December 7 for coverage effective January 1, 2027, affecting more than 70 million enrollees. The out-of-pocket cap for Part D drugs rises to $2,400 from $2,100, and the standard deductible increases from $615 to $700. A temporary Part D premium subsidy will end early at year's end, though CMS projects only modest price increases for most people. Medicare-negotiated prices for 15 drugs, including Ozempic, Wegovy and Rybelsus, take effect January 1, and CMS expects the change to lower prescription drug coverage by $685 million in 2027. Social Security's cost-of-living adjustment of 3.6% adds about $75 a month for nearly 72 million beneficiaries.
- Medicare Open Enrollment Begins , 2027 Plan Changes Announced
Medicare open enrollment begins October 15 and runs until December 7 for coverage starting January 1, 2027, affecting more than 70 million enrollees facing changes to prescription drug coverage and costs. The Social Security Administration will raise cost-of-living adjustments by 3.6% in 2027, about $75 more per month for nearly 72 million beneficiaries. The Part D out-of-pocket cap rises from $2,100 in 2026 to $2,400 in 2027, the standard deductible increases from $615 to $700, and a temporary Part D premium subsidy ends early at year's end. Medicare-negotiated prices for 15 drugs, including Ozempic, Wegovy and Rybelsus, take effect January 1. President Donald Trump also announced one-time payments of $90 in October to more than 20 million enrollees for Part B premiums, costing about $2 billion and excluding roughly 35 million Medicare Advantage enrollees.
- Medicare Open Enrollment Begins , 2027 Plan Changes Announced
Medicare open enrollment starts Thursday, October 15, and runs until December 7 for coverage beginning January 1, 2027, affecting more than 70 million enrollees. The Social Security Administration set a 3.6% cost-of-living increase for 2027, about $75 more per month for nearly 72 million beneficiaries, while the Part D out-of-pocket cap rises from $2,100 to $2,400 and the standard deductible from $615 to $700. A temporary Part D premium subsidy will end early at year’s end, though CMS projects only modest price increases for most people. Medicare-negotiated prices for 15 drugs, including Ozempic, Wegovy and Trelegy Ellipta, take effect January 1. The Trump administration also plans one-time $90 payments in October to more than 20 million enrollees to help with Part B premiums, costing about $2 billion.
- Medicare Open Enrollment Begins , 2027 Plan Changes Announced
Medicare open enrollment runs from October 15 to December 7 for coverage starting January 1, 2027, affecting more than 70 million enrollees facing drug coverage and cost changes. The Part D out-of-pocket cap rises to $2,400 from $2,100, and the standard deductible increases from $615 to $700. A temporary Part D premium subsidy will end early at year's end, though CMS projects only modest increases for most people. Medicare-negotiated prices for 15 drugs, including Ozempic and Wegovy, take effect January 1. Separately, President Trump announced one-time payments of $90 in October to more than 20 million Part B enrollees, excluding roughly 35 million Medicare Advantage enrollees.
- Medicare Open Enrollment Begins , 2027 Plan Changes Announced
Medicare open enrollment runs from Thursday (October 15) to December 7, letting more than 70 million enrollees choose coverage effective January 1, 2027. The Social Security cost-of-living adjustment rises 3.6% in 2027, about $75 more per month for nearly 72 million beneficiaries. The Part D out-of-pocket cap rises from $2,100 to $2,400 and the standard deductible from $615 to $700, while a temporary Part D premium subsidy ends early at year's end. Medicare-negotiated prices for 15 drugs, including Ozempic, Wegovy and Rybelsus, take effect January 1, and CMS estimates the change will lower prescription drug coverage by $685 million in 2027. President Trump announced one-time $90 payments in October for more than 20 million enrollees to help with Part B premiums, costing about $2 billion, but not for roughly 35 million Medicare Advantage enrollees or other groups.
- Medicare Open Enrollment Begins , 2027 Plan Changes Announced
Medicare open enrollment runs from Thursday, Oct. 15, to Dec. 7, letting more than 70 million enrollees choose coverage effective Jan. 1, 2027. Cost-of-living adjustments for Social Security beneficiaries will rise 3.6% in 2027, about $75 more per month for nearly 72 million recipients. The Part D out-of-pocket cap will climb to $2,400 from $2,100, and the standard deductible will rise from $615 to $700. A temporary Part D premium subsidy will end early at year's end, while 15 drugs with Medicare-negotiated prices, including Ozempic and Wegovy, take effect January 1. President Trump also announced one-time $90 payments in October for more than 20 million enrollees, payments that will not reach roughly 35 million Medicare Advantage enrollees.
Related markets
Latest news
- Why Is Nike Stock Falling, and Is It a Buying Opportunity?
Nike's stock has fallen 41.7% over the past year and 76.5% over the past five years, even though the company remains profitable and has a turnaround plan. The article blames a lack of innovation, failure to keep pace with changing consumer tastes, a shift away from wholesalers toward direct sales, and weakness in China, where Greater China sales fell 22% to $1.1 billion in Q1 fiscal 2027. Total first-quarter sales fell 4% to $11.2 billion, and net income fell 2% to $712 million. Nike expects fiscal 2027 revenue to drop by a high-single-digit percentage and plans to cut 1,400 jobs. The author argues there are few near-term catalysts to reignite investor interest, so betting on a rebound carries both risk and opportunity cost.
- Investors look to earnings to reset the bull market. The key level to watch on the S&P 500
The S&P 500 remains in an uptrend but is chopping around a flat 50-day moving average, a level first reached 11 weeks ago. AI-hardware stocks have sold off sharply, bank shares are trading poorly after results, credit markets are under strain, and the Nasdaq has retreated 5%. JP Morgan's Jason Hunter leans cautious, saying a further drop of about 2.5% to 7500 would cost the market the benefit of the doubt. The article recalls 2018, when the S&P 500 fell 19% in the fourth quarter of a midterm year even as earnings grew more than 20%, while tightening now comes from higher Treasury yields, wider credit spreads and a stronger dollar. Bank of America's Aditya Bhave maintains a non-consensus call for an October Fed rate hike, while Morgan Stanley's Mike Wilson argues Chairman Warsh should acknowledge the tightening.
- Why AI could make universal basic income necessary
In the Loop host Ejaaz Ahamadeen explores a scenario in which AI replaces both mental and physical human work, and asks whether higher-order creativity would make universal basic income necessary. He notes that OpenAI, Google, Elon Musk and, by extension, SpaceX have all discussed the idea, with Anthropic taking the first steps in that direction. He argues that human purpose has always been to invent and innovate, and that with more free time people could focus on higher-order thinking, such as managing fleets of AI agents. Still, he admits to an unsettling feeling, since Anthropic's own announcement acknowledged that the resulting disruption is unknown.
- Will Interest Rates or Chips Decide the AI Trade?
On October 19, Jim Cramer said on Mad Money that investors should focus more on interest rates than on whether GPUs hold their value, and set a warning level at a 30-year Treasury yield above 6%. The 30-year yield closed at 5.48% that day, after reaching 5.67% on October 7. The article cites rising pressure on AI infrastructure: Oracle's interest expense rose 55% to $1.4 billion in fiscal Q1 2027 with free cash flow of −$5.4 billion, and Equinix expects its blended cost of capital to rise about 150 basis points. Panelists also flagged a duration mismatch, with long-term debt backed by contracts customers can walk away from, as when Microsoft vacated a UK lease that Anthropic reportedly took over. Nvidia's finance chief projected top-five hyperscaler capex of nearly $800 billion in 2026 and $1.3 trillion in 2027, so a growth slowdown could hit stock prices hard.
- Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo said its next-generation obesity drug CagriSema led to an average 25% weight loss among women at 68 weeks in a new analysis following a late-stage trial, versus 3% with placebo. The result assumes all patients stayed on treatment without interruption, and Novo says further work is needed to confirm two post-study analyses. A separate analysis of about 1,900 women found weight loss of 26.7% in premenopausal, 24.8% in perimenopausal and 23.1% in postmenopausal women. The drug is expected to launch early next year, though investors have been lukewarm after earlier trial results fell short of expectations, and analysts forecast $11.84 billion in 2028 obesity sales per FactSet consensus.
- Up 35%, Should You Buy SpaceX Stock Right Now?
SpaceX (SPCX) shares have risen about 35% from their August low as investor confidence grows, though they remain roughly 10% below their first-day closing price. The company's second-quarter report showed revenue up 92% year over year and a net loss cut almost in half. Starlink subscriptions doubled to 12 million, with more than 11,000 satellites in orbit, while xAI revenue rose 247% and it signed multiyear contracts with Alphabet and Anthropic. The author argues that a price-to-sales multiple of 68, far above the S&P 500's average of 3.8, does not justify the risk given a major lockup ending in December and the company's lack of profit, though he would consider buying at a different valuation.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.